STUDY PROTOCOL

Vacuum-assisted closure versus on-demand relaparotomy in patients with secondary peritonitis—the VACOR trial: protocol for a randomised controlled trial

Pooya Rajabaleyan¹,10*, Jens Michelsen²,10, Uffe Tange Holst¹,10, Sören Möller³, Palle Toft³,10, Jan Luxhoi⁴, Musa Buyukuslu⁴, Aske Mathias Bohm⁵, Lars Borly⁵, Gabriel Sandblom⁶, Martin Kobborg⁷, Kristian Aagaard Poulsen¹,10, Uffe Schou Løve⁶, Sophie Ovesen⁶, Christoffer Grant Sølling⁶, Birgitte Mørch Søndergaard⁶, Marianne Lund Lomholt⁶, Dorthe Ritz Møller⁶, Niels Qvist¹,10, Mark Bremholm Ellebæk¹,10 and The VACOR study group

Abstract

Background: Secondary peritonitis is a severe condition with a 20–32% reported mortality. The accepted treatment modalities are vacuum-assisted closure (VAC) or primary closure with relaparotomy on-demand (ROD). However, no randomised controlled trial has been completed to compare the two methods potential benefits and disadvantages.

Methods: This study will be a randomised controlled multicentre trial, including patients aged 18 years or older with purulent or faecal peritonitis confined to at least two of the four abdominal quadrants originating from the small intestine, colon, or rectum. Randomisation will be web-based to either primary closure with ROD or VAC in blocks of 2, 4, and 6. The primary endpoint is peritonitis-related complications within 30 or 90 days and one year after index operation. Secondary outcomes are comprehensive complication index (CCI) and mortality after 30 or 90 days and one year; quality of life assessment by (SF-36) after three and 12 months, the development of incisional hernia after 12 months assessed by clinical examination and CT-scanning and healthcare resource utilisation. With an estimated superiority of 15% in the primary outcome for VAC, 340 patients must be included. Hospitals in Denmark and Europe will be invited to participate.

Discussion: There is no robust evidence for choosing either open abdomen with VAC treatment or primary closure with relaparotomy on-demand in patients with secondary peritonitis. The present study has the potential to answer this important clinical question.

Trial Registration: The study protocol has been registered at clinicaltrials.gov (NCT03932461). Protocol version 1.0, 9 January 2022.

Keywords: Secondary peritonitis, Faecal peritonitis, Vacuum-assisted closure, Primary abdominal closure, Relaparotomy on-demand

Background

Perforation of the gastrointestinal tract is the most common cause of secondary peritonitis [1, 2]. The underlying conditions may be appendicitis, anastomotic...
dehiscence, perforated diverticulitis, intestinal ischemia, or gastroduodenal ulcer, being the most common [3–7]. Faecal peritonitis is associated with high mortality and morbidity rate, with a reported 28-days mortality up to 20%, increasing to 32% at six-month follow-up [8]. Age, comorbidity, time to intervention, and the extent of peritonitis are important risk factors [7, 9–14]. A prerequisite for non-failure is sufficient source control, antibiotics, and in cases with organ dysfunction, postoperative intensive care treatment may be necessary [15–19]. Despite sufficient treatment, the risk of postoperative abdominal complications is high, and several patients may undergo a reoperation(s) to reveal and treat the complications. Another risk is the development of abdominal compartment syndrome. To manage this, three different strategies may be employed: a planned relaparotomy (PR), a relaparotomy on-demand (ROD), or the open abdomen (OA) principle [2, 5, 20–23]. A randomised controlled trial on PR versus ROD in patients with secondary peritonitis due to gastrointestinal perforation, including 232 patients, showed no significant difference in 1-year mortality (36% vs. 29%) and morbidity (44% vs. 40%) [20]. ROD resulted in significantly fewer relaparotomies and lower hospital-related healthcare costs.

A guideline [19] and consensus report [24] from the World Society of Emergency Surgery recommend ROD or VAC as the preferred treatment strategies for intra-abdominal infections with peritonitis and non-traumatic abdominal emergencies. The benefit of primary abdominal closure and ROD strategy is that patients do not require further scheduled operations. The risk is a delay in treatment for ongoing abdominal sepsis, other serious complications, and abdominal compartment syndrome, which may be difficult to recognize clinically in the severely ill patient [25–28]. Delays in treating severe complications might increase the risk of morbidity and mortality [9, 11, 14]. The advantages of VAC are a planned inspection of the abdominal cavity and the possibility to diagnose and treat potential or overt abnormalities on time. The risk is the development of enteroatmospheric fistula, difficulties in abdominal wound closure, and the development of an incisional hernia [29, 30].

The method with VAC was initially introduced in damage control trauma surgery and has gained increasing use in the treatment of complicated intra-abdominal infections [21, 31–43]. A systematic review and meta-analysis by Atema et al. in 2015 showed an incidence of 14.6% for enteroatmospheric fistula (EAF) and 48.5% for incisional hernias in the group treated with VAC, where 82% of the population was treated for peritonitis. The mortality varied between 21.5 and 30.0%. The VAC procedure can be applied and modified in several ways. The most common are fascial traction methods (mesh mediated or non-mesh mediated), the applied vacuum pressure and the interval for changes of the VAC [42]. The VAC treatment in the present study will be performed with a non-mesh-mediated fascial traction method and narrowing technique. A retrospective study from our institute using this technique, including 115 patients with secondary peritonitis, found a mortality rate of 17% and EAF of 3.5%; secondary closure was obtained in 92% of the patients [44].

The present study will aim to compare the postoperative results of ROD and VAC in patients with secondary peritonitis by a randomised controlled trial with peritonitis-related complications as the primary outcome; comprehensive complication index (CCI), mortality, quality of life, the development of incisional hernia, and hospital care utility and costs were the secondary outcomes.

**Objectives**

- **Primary**
  - Peritonitis-related complications (Table 1) within 30 or 90 days and one year after index surgery
- **Secondary**
  - CCI within 30 or 90 days and one year after index surgery
  - Mortality within 30 or 90 days and after one year
  - SOFA score and C-reactive protein (CRP) measured in the first seven days after index laparotomy
  - Incisional hernia rate after 12 months assessed by clinical examination and abdominal CT-scan
  - Quality of life after 3 and 12 months assessed by the SF-36 questionnaire
  - Hospital care utility within three months after index surgery (Table 2)
- **Tertiary**
  - The concentration of lactate, glycerol, pyruvate, glucose, and cytokines in the peritoneal fluid in a subgroup of 10 patients from each group measured by intraperitoneal microdialysis on postoperative days 0–4

Although the validated CCI may be the best parameter to monitor postoperative complications and morbidity, there are no reliable data in the literature on CCI from this specific group of patients. Therefore, we could not make a meaningful sample size calculation based on CCI alone. Peritonitis-related complications described in the RCT by Van Ruler et al. were the best estimate for the postoperative complications and morbidity we could find in the literature and were used for the study’s sample size calculation [20].
Table 1  Peritonitis-related complications

| Disease-related major morbidity needing readmission and conservative treatment but not surgery |
|--------------------------------------------------|
| Fistula: non-anatomical connection between intestine and cutis, communication between GI tract and external atmosphere or between 2 hollow organs |
| Wound dehiscence/incisional hernia with obstruction: full-thickness discontinuity in the abdominal wall with bulging of abdominal content |
| Abscess needing percutaneous drainage: pus-containing non-pre-existing cavity confirmed by positive Gram stain or culture |
| Renal failure: urine production < 500 mL/24 h with rising levels of blood urea nitrogen and creatinine combined with dehydration (decreased circulating volume with elevated haematocrit needing intravenous rehydration) based on inadequate oral intake, nausea/vomiting, or both (only when needing readmission) |
| Myocardial infarction (electrocardiogram and enzyme changes suggestive of myocardial infarction or needing admission to coronary care unit), pulmonary embolus (ventilation-perfusion mismatch on lung scintigraphy), or cerebrovascular accident (ischemic or non-ischemic with persistent paresis or paralysis without previous history) |
| Gastric or duodenal bleeding: needing endoscopic treatment or embolisation therapy |
| Respiratory failure due to pneumonia, pleural effusion, or pulmonary oedema and needing oxygen therapy or mechanical ventilation |
| Urosepsis: urinary tract infection with positive urine and blood cultures and circulatory shock |

Table 2  Health care utility

| Health care utility |
|---------------------|
| Length of admission at ICU (Total number of days in a three-month period) |
| Length of admission at ward (Total number of days in a three-month period) |
| VAC—Time from index operation to primary closure |
| Total amount of VAC dressing changes (number of times) |
| Number of scheduled VAC changes |
| Number of re-operations with VAC |
| Number of re-operations |
| Number of radiologic interventions during admission(s) |
| Number of computed tomography scans after index operation |
| Number of days alive outside the ICU in a three-month period |

Methods

Study design

A multicentre non-blinded superiority randomised controlled trial on VAC vs. ROD. Danish, as well as other European centres, will be invited to participate. The study protocol adheres to the guidelines determined in Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) (Additional file 2) [45].

The VACOR study will include two separate studies: VACOR-Main and VACOR-Microdialysis.

All centres must participate in the VACOR-Main study, with only Odense University Hospital participating in the VACOR-Microdialysis study. VACOR-Main will report on all primary and secondary outcomes; in VACOR-Microdialysis, a sub-study of 10 patients from each
group will be included. A microdialysis catheter will be placed in the peritoneal cavity, and samples of the peritoneal fluid will be collected every 6th hour to measure the concentration of lactate, glucose, pyruvate, glycerol, cytokines (IL-1β, IL-6, IL-10, TNF-α) and metalloproteins (MMP9 and MMP8). The purpose is to investigate intraperitoneal metabolic changes and inflammatory responses in the two groups.

In-hospital healthcare utility
Three months after the index operation, a record review will be made to estimate the healthcare utility. All data will be retrieved from the electronic patient system and include surgeries, total hospital stay, admissions to the ICU, and radiological interventions (Table 2). For the analysis, unit costs were obtained from the Danish Health Authority. The diagnosis-related groups (DRG) will be used, which express the hospital’s average operating expenses within each DRG group. To ensure comparability between centres, we will utilise the Danish costs for both Danish and international patients.

Study population

Inclusion criteria
Patients eligible for enrolment are 18+ years of age and scheduled for acute laparotomy due to suspected peritonitis originating from perforation of the small bowel, colon, or rectum. To be included, purulent, enteric, or faecal contamination in a minimum of 2 out of 4 quadrants must be confirmed.

Exclusion criteria
- Diffuse peritonitis originating from a perforation on the stomach, duodenum, gallbladder, appendix, necrotising pancreatitis, salpingitis, or peritoneal dialysis
- Primary peritonitis
- Immunocompromised (history of steroid or biological treatment within the last three months or previous organ transplantation)
- Chronic parenchymal liver disease (chronic liver disease with plasma bilirubin above 35 mmol/L)
- Pregnancy
- Patients with end-stage disease (metastatic disease)
- Laparoscopic surgery (not converted to laparotomy)
- Acute occlusion of superior mesenteric artery
- Peritoneal carcinomatosis
- Abdominal trauma
- Lack of consent from the surgical equipoise
- Local peritonitis confined to one quadrant only

Study setting
The study will be conducted in general surgery departments, emergency departments, and operating theatres. The lead centre is Odense University Hospital in Odense, Denmark, a tertiary referral academic medical centre. Other recruiting sites will include academic and community hospitals located in Europe, familiar with the interventions and willing to adhere to the treatment regimens.

Randomisation
Patients are included by a surgical equipoise followed by patient information and consent after recovery. The on-call surgeon will contact the primary investigator from each site when a patient is scheduled for diagnostic laparoscopy or explorative laparotomy on suspicion of secondary peritonitis. Patients fulfilling the inclusion criteria will be randomised after consent has been obtained by the surgical equipoise (Fig. 1). This could occur before, during, or at the end of index laparotomy, disclosing a complete overview of all potential candidates. Most patients will be able to receive both treatments regardless of what arm they are allocated without changing the treatment regimen. However, there will be some exceptions where it is necessary to modify or change the surgical treatment, irrespective of the randomisation allocation. Centres that do not receive approval from their respective scientific ethics committee to include patients through a surgical equipoise must obtain informed and written consent before randomisation. Randomisation will be web-based via (REDCap®) in blocks of 2, 4, and 6 stratified for centre and age above or below 65 years. The justifications for stratifying according to the centre are that there might be differences in the surgical treatment, preoperative optimisation, and postoperative treatment, both in the ward and intensive care unit (ICU), which might affect the outcome. The patients will be randomised to either abdominal closure with ROD or open abdomen with VAC according to transparent reporting of trials (CONSORT) (Fig. 2). The randomisation tool and eligibility criteria can be accessed through our website, www.vacor.sdu.dk.

In cases where the surgeon finds that the allocated treatment may be contraindicated or is judged to harm the patient, it will be left to the surgeon’s discretion to choose the most appropriate treatment. In cases where the bowels are left stapled in discontinuity as a part of the damage control principle, the patient’s fascia cannot be closed due to swelling or the presence of abdominal compartment VAC treatment may be applied irrespective of the randomisation. These patients remain in the trial for an intention-to-treat and per-protocol analysis. By excluding such patients, there might be a risk of selection...
bias. Any eligible patient not included will be registered in a screening log.

Preoperative patient assessment
The patients are preoperatively assessed according to Sequential Organ Failure Assessment (SOFA) to determine the degree of organ dysfunction [46].

Interventions
Vacuum-assisted closure
The VAC® Abdominal Dressing System (KCI Vacuum Assisted Closure, San Antonio, TX, USA) will be used [44]. A video illustrating the procedure is attached in the supplementary material (Additional File 1). Intestines, including lateral aspects, are covered by the visceral protective layer. The first layer of foam is placed in the

Fig. 1 Flowchart of inclusion and obtaining consent by the surgical equipoise
Fig. 2 CONSORT flow diagram
laparostoma on top of the visceral protective layer and must extend below the fascia at a distance of 5 cm from the fascial opening. Above this, a minimum of one piece of foam is folded and placed in the laparostoma. Finally, the laparostoma will be covered by the occlusive drape. A circular opening of approximately 5 cm in diameter will be created in the drape where the connection tubes to the vacuum pump will be placed. Simultaneously, while applying the negative pressure of 125 mmHg, the wound edges are approximated manually towards the midline. The dressing will be changed at an interval of approximately 48 h as standard or whenever needed according to the clinical condition. Each dressing change must be performed with the patient under general anaesthesia and muscle relaxation in the operating theatre. Peritoneal fluid must be cultured at each dressing change and when the fascia is closed. The fascial closure can, in some instances, be difficult due to swelling or the physical inability to close the abdomen. It must commence as soon as possible, judging by intra-abdominal findings, gastrointestinal function, and renal function. The aim will be to close the abdomen within eight days after the index operation.

The fascia closure after VAC treatment can be according to Israelsson’s principle, as described below, or at the surgeon’s discretion. A staged closure may start distally, proximally, or in combination. To ensure the uniformity of intervention in the arm receiving the open management, we have produced a video where the application of the VAC system is demonstrated in a step-by-step manner, as well as providing training for centres not familiar with the technique.

**Primary closure**

The Israelsson principle includes a running suture of the fascia with a distance of 5 mm between the stitches of 5 mm and the distance to the fascial edge of 5–10 mm. Monofilament PDS 2–0 or equivalent is used [47]. The sutting is started cranially and caudally, and the sutures are tied with self-locking knots. Approximately four times as much suture material as the length of the wound must be used or more. The peritoneal fluid must be cultured at closure.

**Relaparotomy on-demand (ROD)**

The treating surgeon decides at daily rounds whether a ROD is required and should be guided by the patient’s general condition, gastrointestinal function, renal function, imaging findings, drain findings, and inflammatory parameters. A planned relaparotomy will not be considered a complication.

**Microdialysis**

The intraperitoneal microdialysis catheter will be placed before the abdominal closure or before applying the VAC system. The microdialysis catheter (M-dialysis 63, Microdialysis AB, Stockholm, Sweden) will be introduced through the abdominal wall outside the laparostoma via a charrier ten split cannula and placed in the peritoneal cavity between small intestine loops. The catheter will be perfused by an isotonic perfusion fluid (Perfusion fluid CNS Dextran, Microdialysis AB, Stockholm, Sweden) via a small pump (Microdialysis CMA 106 pump, Microdialysis AB, Stockholm, Sweden) at a flow rate of 0.3 μl/min. The catheter will be anchored to the skin. Samples will be collected in vials at 6-h intervals for the first four postoperative days. Bedside analysis for lactate, glycerol, and pyruvate concentration will be made via the ISCUS-flex Microdialysis Analyzer (Microdialysis AB, Stockholm, Sweden). After analysis, the samples will be stored at −80 °C to analyse cytokine and MMP concentrations.

**Postoperative patient assessment**

Immediately after index operation, the surgeon fills out the baseline form containing patient characteristics, Charlson comorbidity index, aetiology and extent of the peritonitis, surgical procedure, Mannheims peritonitis index and classification of the OA according to Bjork’s classification [48, 49]. Patients can be transferred postoperatively to the intensive care unit (ICU) or the ward at the discretion of the treating team. Upon arrival to either the ward or the ICU, Acute Physiology and Chronic Health Evaluation II (APACHE II) score must be obtained by the attending anaesthesiologist [46, 50]. SOFA-scoring and routine blood samples with CRP, bilirubin, creatinine, and platelets must be performed daily within the first seven days after index operation. Discharge from the ICU will be at the discretion of the attending intensivist and surgeon.

**Follow-up**

At hospital discharge, the patients will be booked for follow-up after 12 months in the outpatient clinic for abdominal palpation and abdominal CT-scan with intravenous contrast and Valsalva manoeuvre. In addition, the SF-36 questionnaire will be completed at the 3- and 12-month follow-up.

**Data collection and participant timeline**

The pre- and perioperative assessment will consist of: baseline data (sex, age, surgery date, height, weight, body mass index, ASA score, WHO performance score, smoking, alcohol consumption, presence of comorbidities, previous abdominal surgeries, and steroid use). Data for
surgical findings include aetiology of disease, anatomical location of intestinal perforation, degree of contamination, surgical treatment, method of abdominal wall closure, and suture material used for abdominal wall closure. Postoperative monitoring consists of SOFA, APACHE II, CRP, VAC treatment duration, unplanned VAC change, and the number of laparotomies in the ROD group. A patient record review will be performed at the follow-up after one month, three months, one year, and five years (Fig. 3). All data will be stored in REDCap®, hosted by the Odense Patient data Explorative Network (OPEN).

**Sample size and power**

With an expected peritonitis-related complications rate of 40% in the ROD group [20] and 25% in the VAC group [42, 44], the desired power of 80%, a significance level of 0.05, and an expected drop-out of 5%, a total of 340 patients should be included.

As the CCI distribution in this group of patients is unknown, we could not perform an explicit sample size calculation for this secondary outcome. A 0.32 standard deviation difference in mean CCI between the two groups could be detected with 80% power with this sample size.

To ensure sufficient recruitment, the study will be multicentre and European. Eight active centres have been included, and two are in process. Randomisation tools along with eligibility criteria are accessible through our website. The workflow and relevant contact details appear on posters at the participating departments. Study progress will be available on the website.

**Statistical analysis**

Patient characteristics will be summarised with frequencies and proportions (for categorical variables) or with mean values ± standard deviation, median values, quartiles, and minimum and maximum values (for numerical variables). Categorical variables will be compared using a Fisher’s exact test and continuous variables with a Wilcoxon rank-sum test.

The primary peritonitis-related complication outcome will be compared between intervention groups by the Chi-square test, reported as relative risk with a 95% CI. The CCI outcome will be compared by linear regression with bootstrapped standard errors reporting the mean difference with 95% confidence intervals.

The main analysis will be performed as a superiority analysis of VAC treatment against primary closure with ROD. In addition, a non-inferiority analysis with a margin of 5% will be reported for peritonitis-related complications as a secondary analysis.

A univariate analysis will be performed on the individual complication types (abscess, leakage, etc.) and complications as a whole (peritonitis-related complications and CCI). Fisher’s exact or Chi-square test will be used to compare the treatments depending on the number of observations.

Adjusted analysis by logistic regression will be performed for complications as a whole and the individual complications as an outcome, adjusted for age, performance status, and comorbidity. The above analyses will also be performed as a subgroup analysis where patients with APACHE II score > 10 will be included. This evaluates VAC and ROD in the most seriously ill portion of the patient population.

The hospital healthcare utility and average treatment costs are compared between the treatment groups. The resource use will be reported as the mean difference with 95% confidence intervals (CI) compared by linear regression. In case of deviations from normality assumptions, bootstrapping with 1000 repetitions will be performed. Finally, the proportion of patients who experience radiological, acute operations will be compared by binomial regression estimating relative risk (RR) with 95% CI.

The interim analysis will be performed at 25%, 50%, and 75% of recruited patients on the primary outcome after 30-days to detect significant differences between groups at the earliest possible time, ultimately leading to the termination of the study. We have adjusted our power calculation to the interim analyses using the O’Brien–Fleming method. The study group will have access to the results of the interim analyses and may make the final decision to terminate the study.

All of the above analyses will be performed as both intention-to-treat (patients will be analysed according to their randomisation group) and per-protocol analysis (what actually happened). The main analyses will be performed as complete case analyses. Multiple imputations will impute missing values in a supplementary analysis, including baseline characteristics as predictors. 

$P$ values < 0.05 will be considered statistically significant. Statistical calculations will be performed using Stata software (version 15, Stata Corp LP, Texas, USA).

In the VACOR-Microdialysis sub-study, the parameters will be compared using descriptive statistics for continuous and discrete variables. Repeated measurement across time points will be compared by mixed-effects regression models, including the interaction between time points and operation method and a random intercept for each patient. In addition, normality assumptions will be graphically assessed using quantile-quantile plots.
| TIMEPOINT**     | Potential subject | Enrolment | Allocation | Post-allocation | Follow-up | Close-out |
|----------------|-------------------|-----------|------------|-----------------|-----------|-----------|
|                | 0                 | 0         | 0          |                 | 1 month   | 3 months  | 1 year    |
| **ENROLMENT:** |                   |           |            |                 |           |           |
| Eligibility screen |                   | X         |            |                 |           |           |
| Informed consent |                   |           |            | X               |           |           |
| Consent from surgical equipoise |               | X         |            |                 |           |           |
| Allocation |                   |           |            | X               |           |           |
| **INTERVENTIONS:** |                   |           |            |                 |           |           |
| [Primary closure with relaparotomy “on-demand”] |               |           |            |                 |           |           |
| [Vacuum-assisted closure] |               |           |            |                 |           |           |
| **ASSESSMENTS:** |                   |           |            |                 |           |           |
| [Baseline] |                   | X         |            |                 |           |           |
| [Operative record] |               |           |            | X               |           |           |
| [Björck's classification] |               |           |            | X               |           |           |
| [Mannheims peritonitis index] |               |           |            | X               |           |           |
| [APACHE II] |                   |           |            | X               |           |           |
| [SOFA] |                   |           |            | X               |           |           |
| [Microdialysis] |               | X         |            | X               |           |           |
| [Microbiological sampling] |               | X         |            | X               |           |           |
| [Peritonitis related complications] |               |           |            |                 | X         | X         |
| [Health related resource use and costs] |               |           |            |                 | X         |           |
| [Clavien-Dindo] |               | X         |            | X               | X         | X         |
| [SF-36 Questionnaire] |               |           |            |                 | X         | X         |
| [1-year follow-up] |               |           |            |                 | x         |           |
| [Hernia rate] |                   |           |            |                 | X         |           |

Fig. 3 Participant timeline
**Discussion**

The VACOR trial addresses several important unanswered clinical questions in the surgical treatment of complicated intra-abdominal infections with special reference to the choice of primary abdominal closure with ROD or the open abdomen with VAC treatment.

In some conditions such as severely complicated peritonitis, second look for ischemia and septic shock, where patients have substantial visceral oedema with high risks of abdominal compartment syndrome, establishing an OA with VAC may be preferred [5, 17, 19, 24]. According to intention-to-treat and per-protocol principles, these patients will be included in the present study. The OA with VAC treatment may have several benefits, including drainage of residual infection, preventing intra-abdominal compartment syndrome, and the timely treatment of complications. The disadvantages are incisional hernia and EAF [23, 42, 44, 51–55]. A recent review of temporary abdominal closure techniques found a higher incidence of EAF in septic than non-septic patients (12.1% vs. 3.7%, respectively) [56]. A large cohort study by Coccolini et al. [57], including 649 patients treated with OA where most patients had peritonitis, could not confirm that peritonitis or temporary abdominal closure with or without negative pressure was related to the incidence of EAF. In systematic reviews with meta-analyses and non-randomised studies it has been shown that VAC is the safest of all temporary abdominal closure techniques [21, 31–43].

In a study including patients with severe secondary peritonitis, patients were randomised to OA with non-resorbable polypropylene mesh versus primary closure with ROD [58]. The study was discontinued at the first interim analysis. The study showed an insignificant higher mortality risk in the OA group of 55% compared to 30% in the ROD group. However, there was a relative risk of 1.83 and an odds ratio of 2.85 in the OA group. Hence, the authors concluded a tendency towards a better outcome in the ROD group.

Animal and in silico studies suggest that VAC treatment suppresses systemic inflammatory reactions and prevents multi-organ failure by draining the peritoneal fluid [59, 60]. In a small animal study comparing VAC to passive drainage after inducing abdominal sepsis, the mortality rate was 17% versus 50%. This difference was not statistically significant \( (p=0.19) \), likely due to the small number of included animals [60]. In the only human RCT, levels of plasma and peritoneal cytokines in patients with abdominal trauma and intra-abdominal sepsis were compared [61]. Participants were allocated to Barker’s or vacuum pack. The study revealed no significant difference in bio-mediator levels or peritoneal drainage. However, a significant difference was observed in 90-day mortality (21.7% vs. 50%), favouring the VAC group. No human RCT studies compare bio-mediators in VAC versus primary closure with ROD.

Diagnosing postoperative or ongoing abdominal complications with the ROD strategy can sometimes be challenging. The literature suggests that progressive or persistent organ failure in the early postoperative phase is the best indicator of positive findings and ongoing infection [20, 26, 62]. The choice of whether or not to perform a relaparotomy is often subjective, based on local guidelines and personal experiences [25–28]. In a randomised study 112 patients with secondary peritonitis were included in the ROD group and 113 in the planned relaparotomy arm [20]. A total of 42% of patients in the ROD group received relaparotomies, 71% had negative findings, and 29% had positive findings at the relaparotomy, respectively.

As well as our study, another randomised multicentre trial, the COOL study [63], is actively recruiting patients with secondary peritonitis to either VAC or primary closure. The primary endpoint is the 90-day mortality rate. The COOL study includes severely ill patients, assessed by physiological scores and secondary peritonitis originating from the lower- and upper gastrointestinal tract, gallbladder, and adnexa. The current study includes patients with secondary peritonitis from the lower gastrointestinal tract with purulent, enteric, or faecal contamination in a minimum of two out of four abdominal quadrants, irrespective of the patient’s general condition. Therefore, there is a risk that some patients may be overtreated. However, the risk might be low since we have excluded patients with upper GI perforations, appendicitis, pancreatitis, and local peritonitis. The majority of the patients are expected to be septic, and the literature has indicated that these patients may benefit from VAC treatment [17, 19, 24]. There might be a grey zone of precisely which patients may benefit from VAC treatment. The COOL trial includes only cases where the surgeon a priori finds that VAC might be beneficial before the randomisation takes place. Our study explores the generalisability of VAC or abdominal closure as the main principle in patients with diffuse peritonitis from the...
lower gastrointestinal tract. Our study and the COOL study utilise inclusion via a surgical equipoise, ensuring that a high fraction of eligible patients will be included.

A limitation of the current study is that the power calculation is based on peritonitis-related complications and not the CCI-index due to the literature lacking explicit results for VAC and ROD. The abdominal condition at index operation will be classified according to Bjorck’s amended classification [48]. The system was intended for established open abdomens rather than the abdominal condition at the index operation. Nonetheless, it is a novel usage for this reviewer. However, this might be another valuable aspect of our study to comment upon whether the classification is further helpful for general use in acute general surgery.

Conclusions

There is no robust evidence for choosing either open abdomen with VAC treatment or primary closure with relaparotomy on-demand in patients with secondary peritonitis. The present study has the potential to answer this important clinical question.

Abbreviations

VAC: Vacuum-assisted closure; PR: Planned relaparotomy; ROD: Relaparotomy ‘on-demand’; CCI: Comprehensive complication index; SF-36: Short form survey 36; OA: Open abdomen; EAF: Enteroatmospheric fistula; CT: Computed tomography; CRP: C-reactive protein; CI: Confidence interval; OPEN: Odense Patient data Explorative Network; ASA: American Society of Anesthesiology; APACHE II: Acute Physiology and Chronic Health Evaluation II; SOFA: Sequential Organ Failure Assessment; ICU: Intensive care unit; DRG: Diagnosis-related groups.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s13071-022-00427-x.

Additional file 1. Video illustrating the application of the VAC system.

Additional file 2. SPIRIT Checklist.

Acknowledgements

Not applicable.

The VACOR study group: Jens Michelsen (UM) (Jens.Michelsen3@rsyd.dk, Research Unit for Anaesthesiology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark); Uffe Tangen Holst (UTH) (Uffe.Tangen.Holst@rsyd.dk, Research Unit for Surgery, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark); Sören Møller (SM) (Soren.Moller@rsyd.dk, OPEN, Open Patient data Explorative Network, Odense University Hospital and Department of Clinical Research, University of Southern Denmark, Odense, Denmark); Palle Toft (PT) (Palle.Toft@rsyd.dk, Research Unit for Anaesthesiology, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark); Jens Lysholm (JL) (Jen.Lysholm@rsyd.dk, Surgical Department, Hospital of Southwest Jutland, Finsensgade 35, 6700 Esbjerg, Denmark); Musa Buyukuslu (MB) (Musa.Buyukuslu@rsyd.dk, Surgical Department, Hospital of Southwest Jutland, Finsensgade 35, 6700 Esbjerg, Denmark); Askie Mathias Bohm (AB) (asbo@regionsjaeldk.dk, Surgical Department, Holbaek Hospital, Smedelundsgade 60, 4300 Holbaek, Denmark); Lars Borly (LB) (lborly@regionsjaeldk.dk, Surgical Department, Holbaek Hospital, Smedelundsgade 60, 4300 Holbaek, Denmark); Gabriel Sandblom (GS) (gabriel.sandblom@ki.se, Karolinska Institute, Surgical Department, Sodersjukhuset, Sjukhusbacken 10, 118 83 Stockholm, Sweden); Martin Kobborg (MK) (Martin.Kobborg@rsyd.dk, Surgical Department, Kolding Hospital, Sygehusvej 24, 6000 Kolding, Denmark); Kristian Agaard Poulsen (KAP) (Kristian.poulsen@rsyd.dk, Surgical Department, Odense University Hospital/Svendborg, Baagaes Allé 31, 5700 Svendborg, Denmark); Uffe Schou Lave (USL) (uffescho@rm.dk, Surgical Department, Viborg Hospital, Heibergs Allé 4, 8800 Viborg, Denmark); Sophie Ovesen (SO) (Sopove@rm.dk, Surgical Department, Viborg Hospital, Heibergs Allé 4, 8800 Viborg, Denmark); Christoffer Grant Salling (CG) (chrsoel@rm.dk, Department of anaesthesiology, Viborg Hospital); Birgitte March Søndergaard (BM) (bitsen@rm.dk, Surgical Department, Viborg Hospital); Marianne Lund Lomholt (MLL) (marianne.lomholt@rm.dk, Surgical Department, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200 Aarhus, Denmark); Dorthe Ritz Møller (DRM) (dorthmel@rm.dk, Surgical Department, Aarhus University Hospital, Palle Juul-Jensens Blvd. 99, 8200 Aarhus, Denmark; Niels Qvist (NQ) (Niels.Qvist@rsyd.dk, Research Unit for Surgery, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense Denmark); Mark Bremholm Ellebæk (MBE) (Mark.Ellebaek1@rsyd.dk, Research Unit for Surgery, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark); Mark Bremholm Ellebæk (MBE) (Mark.Ellebaek1@rsyd.dk, Research Unit for Surgery, Odense University Hospital, Odense, Denmark; University of Southern Denmark, Odense, Denmark)

Trial status

Recruitment has been active since June 2020 and is estimated to be completed in 2024–2025.

Author contributions

PR, JM, UTH, PT, NQ, and MBE designed the trial and drafted the protocol. SM contributed to the power calculation and statistical design. JL, MB, AB, LB, GS, MK, KAP, USL, SO, CG, BM, MLL, and DRM discussed and critiqued the data and its interpretation. All authors read and approved the final manuscript.

Funding

The study is funded by the University of Southern Denmark, Region of Southern Denmark, and Novo Nordisk Foundation (Grant Nos: NNF19OC0058637, NNF19OC0058637, A301). Trial Sponsor: University of Southern Denmark, Campusvej 55, 5230 Odense M, Denmark. Email: info@novonordiskfonden.dk. The sponsors have no influence on the study design or interpretation of data.

Availability of data and materials

On request, data can be shared in an anonymised form if a data processor agreement is obtained.

Declarations

Ethics and consent to participate

The study will be conducted in accordance with the Declaration of Helsinki and complies with current GDPR recommendations. The Regional Danish Medical Ethics Committee has approved the study to include patients in the acute setting with temporary consent by a surgical equipoise followed by patient information and consent after recovery. The surgical equipoise must not have any personal interest in the experiment, experience, or know about the disease and the risks and benefits of the treatments. It must be indifferent to the therapeutic value of the two interventions. The rationale for choosing this inclusion model was that the subjects requiring immediate surgical intervention are partially or entirely incapable of receiving and understanding the information. The severity of the condition does not allow time for third-party authorisation. Both treatment regimens are accepted, safe, and widely used for this patient group. The COOL investigators have made a comprehensive review of Surgical Ethics that further justifies the arguments for using consent by surgical equipoise [64]. After the convalescence, patients will be informed about the project, and consent will be obtained. Surrogate consent will be obtained when the patients do not survive before regaining a habitual state. The patient can withdraw from the experiment at any time without having to explain their reasons. To ensure patient safety, we will perform three interim analyses.
Patients in Denmark are covered by national insurance (Patienterstatningen), and international centres use country-specific insurance regulations. The study is investigator-initiated without economic interest to manufacturers or others involved in the investigation. No financial resources will be provided to the trial participants. Participating centres will receive the amount of 4000 Danish Krone per included patient yearly to cover the CT-scan of the abdo-
men and follow-up at the outpatient clinic. The final data set will be available to the project owner and data assessor. Data can be shared in a pseudonymised form after an approved agreement on request. The primary investigator is responsible for data collection and handling. Protocol modifications must be reported to the regional ethics committee.

Consent for publication
Not applicable.

Competing interests
The primary investigator and collaborators have no financial interest in the trial.

Author details
1. Research Unit for Surgery, Odense University Hospital, Odense, Denmark.
2. Research Unit for Anaesthesiology, Odense University Hospital, Odense, Denmark. 3. OPEN, Open Patient Data Explorative Network, Odense University Hospital and Department of Clinical Research, University of Southern Den-
mark, Odense, Denmark. 4. Surgical Department, Hospital of Southwest Jutland, Esbjerg, Denmark. 5. Surgical Department, Holbæk Hospital, Holbæk, Denmark. 6. Karolinska Institute, Stockholm, Sweden. 7. Surgical Department, Kolding Hospital, Kolding, Denmark. 8. Surgical Department, Viborg Hospital, Viborg, Denmark. 9. Surgical Department, Aarhus University Hospital, Århus, Denmark. 10. University of Southern Denmark, Odense, Denmark.

Received: 10 February 2022 Accepted: 11 May 2022
Published online: 26 May 2022

References
1. Malagoni MA, Inui T. Peritonitis—the Western experience. World J Emerg Surg. 2006;1:25.
2. Pieracci FM, Barie PS. Management of severe sepsis of abdominal origin. Scand J Surg. 2007;96(3):184–96.
3. Ordoñez CA, Puyana JC. Management of peritonitis in the critically ill patient. Surg Clin North Am. 2006;86(6):1233–49.
4. Mulari K, Leppäniemi A. Severe secondary peritonitis following gastroin
testinal tract perforation. Scand J Surg. 2004;93(3):204–8.
5. Sartelli M, Catena F, di Saverio S, Ansaloni L, Malangoni M, Moore EE, et al. Current concept of abdominal sepsis: WSES position paper. World J Emerg Surg. 2014;9(1):22.
6. Gavriel R, Pian V, Barth X, Mistretta F, Lalonde O. Epidemiology, management, and prognosis of secondary non-postoperative peritonitis: a french prospective observational multicenter study. Surg Infect. 2009;10(2):119–27.
7. Sartelli M, Catena F, Ansaloni L, Leppäniemi A, Tavoliglio V, van Goor H, et al. Complicated intra-abdominal infections in Europe: a comprehen-
sive review of the CIAO study. World J Emerg Surg. 2012;7(1):36.
8. Trindade A, Clarke GM, Walden A, McKechnie S, Hutton P, Mills GH, et al. Patients with faecal peritonitis admitted to open intensive care units: an epidemiological review of the GenOSept cohort. Intensive Care Med. 2014;40(2):202–10.
9. Anaya DA, Nathens AB. Risk factors for severe sepsis in secondary peritonitis. Surg Infect. 2003;4(4):355–62.
10. Bohm JMA, Mustard RA, Oxholm SE, Schouten BD. APACHE II score and abdominal sepsis: a prospective study. Arch Surg. 1988;123(2):225–9.
11. Ohmann C, Wittmann DH, Wach A. Prospective evaluation of prognostic scoring systems in peritonitis. Eur J Surg. 1993;159(5):672–74.
12. Wach A, Haas T, Dittmer R, Ohmann C, Aebenhard A, Billing A, et al. Risk factors associated with intraabdominal infections: a prospective multi-
center study. Langenbecks Arch Surg. 1990;384(1):24–32.
13. Hyninnen M, Wernervirta J, Leppäniemi A, Pettila V. Organ dysfunction and long term outcome in secondary peritonitis. Langenbecks Arch Surg. 2008;393(1):81–6.
14. Tolonen M, Sallinen V, Mentula P, Leppäniemi A. Preoperative prognostic factors for severe diffuse secondary peritonitis: a retrospective study. Langenbecks Arch Surg. 2016;40(5):611–7.
15. Tellor B, Skrupky LP, Symons W, High E, Miek CL, Maksi MAJ. Inadequate source control and inappropriate antibiotics are key determinants of mortality in patients with intra-abdominal sepsis and associated bactere-
ia. Surg Infect. 2015;16(6):785–93.
16. Sartelli M, Catena F, Ansaloni L, Cocolin F, Corbellà D, Moore EE, et al. Complicated intra-abdominal infections worldwide: the definitive data of the CIAOW Study. World J Emerg Surg. 2014;9(1):37.
17. Sartelli M, Catena F, Abu-Zidan FM, Ansaloni L, Biffl WL, Boermeester MA, et al. Management of intra-abdominal infections: recommendations by the WSES 2016 consensus conference. World J Emerg Surg. 2017;12:22.
18. Ross JT, Matthy AU, Harris RW. Secondary peritonitis: principles of diagnosis and intervention. BMJ. 2018;361:k1407.
19. Sartelli M, Chichorm-Mefire A, Labriciosa FM, Hardtcastle T, Abu-Zidan FM, Adesunkanmi AK, et al. The management of intra-abdominal infections from a global perspective: 2017 WSES guidelines for management of intra-abdominal infections. World J Emerg Surg. 2017;12:29.
20. van Ruler O, Mahler CW, Boer KR, Reuland EA, Goossen HG, Opmeer BC, de Graaf PW, Lamme B, Gerhards ME, Steller EP, van Till JW, de Borde CJ, Gouma DJ, Reitsma JB, Boermeester MA. Dutch Peritonitis Study Group. Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: a randomized trial. JAMA. 2007;298(8):865–72.
21. Turza KC, Campbell CA, Rosenberg LH, Politano AD, Davies SW, Riccio LM, et al. Options for closure of the infected abdomen. Surg Infect. 2012;13(6):343–51.
22. Ciochi R, Birindelli A, Biffl WL, Mutafchyski V, Popivanov G, Chiara O, et al. What is the effectiveness of the negative pressure wound therapy (NPWT) in patients treated with open abdomen technique? A systematic review and meta-analysis. J Trauma Acute Care Surg. 2016;81(3):575–84.
23. Lamme B, Boermeester MA, Belt EJT, van Till JW, Gouma DJ, Obertop H. Mortality and morbidity of planned relaparotomy versus relaparotomy on demand for secondary peritonitis. Br J Surg. 2004;91(8):1046–54.
24. Cocolin F, Montori G, Ceresoli M, Catena F, Moore EE, Ivatury R, et al. The role of open abdomen in non-trauma patient: WSES consensus paper. World J Emerg Surg. 2017;12:39.
25. van Ruler O, Kiewiet JJS, Boer KR, Lamme B, Gouma DJ, Boermeester MA, et al. Failure of available scoring systems to predict ongoing infection in patients with abdominal sepsis after their initial emergency laparotomy. BMC Surg. 2011;11:38.
26. Hutchins RR, Gunnig MP, Lucas DN, Allen-Mersh TG, Soni NC. Relaparotomy for suspected intraabdominal sepsis after abdominal surgery. World J Surg. 2004;28(2):137–41.
27. Bader FG, Schröder M, Kujath P, Muhl E, Bruch HP, Eckmann C. Diffuse postoperative peritonitis: value of diagnostic parameters and impact of early indication for relaparotomy. Eur J Med Res. 2009;14(11):491–6.
28. van Ruler O, Lamme B, Gouma DJ, Reitsma JB, Boermeester MA. Variables associated with positive findings at relaparotomy in patients with sec-
ondary peritonitis. Crit Care Med. 2007;35(2):468–76.
29. Demetriades D, Salim A. Management of the open abdomen. Surg Clin North Am. 2014;94(1):13–9.
30. Regnér JL, Kobayashi L, Coimbra R. Surgical strategies for management of the open abdomen. World J Emerg Surg. 2012;36(3):497–508.
31. Horwood JD, Actbar F, Maw A. Initial experience of laparostomy with imme-
diate vacuum therapy in patients with severe peritonitis. Ann R Coll Surg Engl. 2009;91(8):681–7.
32. Amin AI, Shaikh IA. Topical negative pressure in managing severe perito-
ronitis: a positive contribution? World J Gastroenterol. 2009;15(27):3394–7.
33. Tolonen M, Mentula P, Sallinen V, Rašilainen S, Bäcklund M, Leppäniemi A. Open abdomen with vacuum-assisted wound closure and mesh-
mediated fascial traction in patients with complicated diffuse secondary peritonitis: a single-center 8-year experience. J Trauma Acute Care Surg. 2017;82(6):1100–5.
34. Woodberg D, Larsson HJ, Metzger U, Platz A, Zingg U. Treatment of the open abdomen with the commercially available vacuum-assisted closure system in patients with abdominal sepsis: low primary closure rate. World J Emerg Surg. 2008;32(12):2724–9.
35. Plaudis H, Rudzats A, Melberga L, Kazaka I, Suba O, Pupelis G. Abdominal negative-pressure therapy: a new method in countering abdominal compartment and peritonitis—prospective study and critical review of literature. Ann Intensive Care. 2012;2(1):523.

36. Perez D, Wildi S, Demartines N, Bramkamp M, Koehler C, Clavien PA. Prospective evaluation of vacuum-assisted closure in abdominal compartment syndrome and severe abdominal sepsis. J Am Coll Surg. 2007;205(4):586–92.

37. Fortelny RH, Hofmann A, Gruber-Blum S, Petter-Puchner AH, Glaser KS. Delayed closure of open abdomen in septic patients is facilitated by combined negative pressure wound therapy and dynamic fascial suture. Surg Endosc. 2014;28(7):335–40.

38. Schmelze M, Allerdinger I, Matthaei H, Aydin F, Wallert I, Eisenberger CF, et al. Long-term vacuum-assisted closure in open abdomen due to secondary peritonitis: a retrospective evaluation of a selected group of patients. Dig Surg. 2010;27(4):272–8.

39. Muratçıyıskı VM, Popvanır-Gül, Köseoğlu KT, Chipova S. Open abdomen and VAC in severe diffuse peritonitis. J R Army Med Corps. 2016;162(1):30–4.

40. Pliakos I, Papavramidis TS, Mihalopoulos N, Kouroubis H, Kessigoulou I, Sапалдис K, et al. Vacuum-assisted closure in severe abdominal sepsis with or without retention surrended sequential fascial closure: a clinical trial. Surgery. 2010;148(5):947–53.

41. Rauhse S, Amico F, Frattini F, Rovera F, Boni L, Dionigi G. A review on vacuum-assisted closure therapy for septic peritonitis open abdomen management. Surg Technol Int. 2014;25:68–72.

42. Atema JJ, Gans SL, Boermeester MA. Systematic review and meta-analysis of the open abdomen and temporary abdominal closure techniques in non-trauma patients. World J Surg. 2013;39(4):912–25.

43. Bertelsen CA, Fabricius R, Klejf J, Kristensen B, Gögenur I. Outcome of negative-pressure wound therapy for open abdomen treatment after nontraumatic lower gastrointestinal surgery: analysis of factors affecting delayed fascial closure in 101 patients. World J Surg. 2013;38(4):774–81.

44. Hougaard HT, Ellebaek M, Holst UT, Qvist N. Delayed fascial closure in 101 patients. World J Surg. 2013;38(4):774–81.

45. Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013;346:e7586.

46. Vincent JL, Moreno R, Takala J, Willatts S, de Mendonça A, Bruining H, et al. The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/ failure. Intensive Care Med. 1996;22(7):707–10.

47. Israelsson LA, Millbourn D. Closing midline abdominal incisions. Langenbecks Arch Surg. 2012;397(8):1201–7.

48. Björck M, Kirkpatrick AW, Cheatham M, Kaplan M, Leppäniemi A, de Waele JJ. Amended classification of the open abdomen. Scand J Surg. 2016;105(1):5–10.

49. Charlton ME, Pompei P, Ales KL, Mackenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.

50. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE—acute physiology and chronic health evaluation: a physiologically based classification system. Crit Care Med. 1981;9(8):591–7.

51. Santelli M, Abu-Zidan FM, Ansaloni L, Bala M, Beltrán MA, Biffi WL, et al. The role of the open abdomen procedure in managing severe abdominal sepsis: WSES position paper. World J Emerg Surg. 2015;10:35.

52. Trevelyan SL, Carlson GL. Is TNP in the open abdomen safe and effective? J Wound Care. 2009;18(1):24–5.

53. Rao M, Burke D, Finan PJ, Sagar PM. The use of vacuum-assisted closure of abdominal wounds: a word of caution. colorectal Dis. 2007;9(3):266–8.

54. Mintziras I, Milagkos M, Bartsch DK. High risk of fistula formation in vacuum-assisted closure therapy in patients with open abdomen due to secondary peritonitis—a retrospective analysis. Langenbecks Arch Surg. 2016;401(5):619–25.

55. Bradley MJ. Independent predictors of enteric fistula and abdominal sepsis after damage control laparotomy. JAMA Surg. 2013;148(10):947–54.

56. Buhram A, Ferreira F, Chankri M, Smith J, Runkel N. Systematic review and evidence based recommendations for the use of negative pressure wound therapy in the open abdomen. Int J Surg. 2014;12(10):1105–14.

57. Coccolini F, Ceresoli M, Kluger Y, Kirkpatrick A, Montori G, Salvetti F, et al. Open abdomen and entero-atmospheric fistulae: an interim analysis from the international register of open abdomen (IROA). Injury. 2019;50(1):160–6.

58. Robledo FA, Luque-De-León E, Suárez R, Sánchez P, De-La-Fuente M, Vargas A, et al. Open versus closed management of the abdomen in the surgical treatment of severe peritonitis: a randomized clinical trial. Surg Infect. 2007;8(1):63–72.

59. Emr B, Sadowsky D, Azhar N, Gatto LA, An G, Nieman GF, et al. Removal of inflammatory ascites is associated with dynamic modification of local and systemic inflammation along with prevention of acute lung injury: in vivo and in silico studies. Shock. 2014;41(4):317–23.

60. Kubiak BD, Albert SP, Gatto LA, Snyder KP, Maier KG, Vieau CJ, et al. Peritoneal negative pressure therapy prevents multiple organ injury in a chonic porcine sepsis and ischemia/reperfusion model. Shock. 2010;34(5):525–34.

61. Kirkpatrick AW, Roberts DJ, Faris PD, Ball CG, Kubes P, Tiruta C, et al. Active negative pressure peritoneal therapy after abbreviated laparotomy: the intraperitoneal vacuum randomized controlled trial. Ann Surg. 2015;262(1):38–46.

62. Lamme B, Mahler CW, van Ruler O, Gouma DJ, Retisma JB, Boermeester MA. Clinical predictors of ongoing infection in secondary peritonitis: systematic review. World J Surg. 2006;30(12):2170–81.

63. Kirkpatrick AW, Coccoli F, Ansaloni L, Roberts DJ, Tolonen M, McKee JL, et al. Closed Or open after source control laparotomy for severe complicated intra-abdominal sepsis (the cool trial): study protocol for a randomized controlled trial. World J Emerg Surg. 2018. https://doi.org/10.1186/s13017-018-0183-4.

64. Doig CJ, Page SA, McKee JL, Moore EE, Abu-Zidan FM, Carroll R, et al. Ethical considerations in conducting surgical research in severe complicated intra-abdominal sepsis. World J Emerg Surg. 2019;14:39.

**Publisher’s Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.